Michel Dahan has sold AKBA and made no open-market buys since Aug 2017
SVP and COO at Akebia Therapeutics, Inc.
SEC CIK 0001669737 · Filings on SEC.gov ↗
$0Bought
$516KSold
NoneLast buy
Every filing
8 filings since Aug 2017, newest first
AKBASell
Akebia Therapeutics, Inc.
SVP and COO
$44K−5.0%May 14
AKBASell
Akebia Therapeutics, Inc.
SVP and COO
$117K−14.0%May 25
AKBASell
Akebia Therapeutics, Inc.
SVP and COO
$47K−7.0%Mar 2
AKBASell
Akebia Therapeutics, Inc.
SVP and COO
$49K−5.0%Mar 2
AKBASell
Akebia Therapeutics, Inc.
SVP and COO
$61K−3.0%Mar 2
AKBASell
Akebia Therapeutics, Inc.
SVP and Chief Business Officer
$27K−1.0%Oct 4
AKBASell
Akebia Therapeutics, Inc.
SVP and Chief Business Officer
$97K−5.0%Oct 2
AKBASell
Akebia Therapeutics, Inc.
SVP and Chief Business Officer
$75K−5.0%Aug 17
Filings come from SEC EDGAR. Not investment advice.